Register for the 2nd RADAR-base Symposium

We are delighted to share that the RADAR-base Symposium 2023 will take place in person at De Stadstuin in Utrecht, Netherlands, on the 20th of April, 2023.

Register for free here

This second edition of the RADAR-base Symposium is dedicated to exploring the latest developments in the field of Mobile Health and bringing together experts from around the world to discuss the impact of mobile technology on healthcare. This event is also a great opportunity to hear from industry leaders and top scientists as they share their insights, experiences, and visions for the future.

This year's symposium promises to be an exciting and informative event with a packed schedule of presentations. The symposium will focus on real-life use cases leveraging mobile phone data, wearable sensors, and digital health biomarkers in various medical domains − from COVID to Alzheimer's disease and from stress resilience to oncology. You can also participate in our Poster Session and get a chance to win exciting prizes!

Join this free annual community meeting to learn how researchers leverage the RADAR-base platform in different medical domains, meet the developers, hear about newly released features, and discuss the roadmap for the future. The event is also a great opportunity to and newly released features and to discuss the exciting possibilities of remote data collection and analysis as an integral part of digital health.

Whether you are a healthcare professional, researcher, entrepreneur, or technology enthusiast, this event is not to be missed. So join us in Utrecht on the 20th of April to unlock the power of mobile technology in healthcare and learn how it changes healthcare and wellbeing.

You can find the symposium agenda and registration details here.

For questions and additional information, contact Jessica Singh (jessica@thehyve.nl).

Funding statement and Disclaimer

The RADAR-base platform was developed under projects IMI RADAR-CNS, IMI RADAR-AD, Bigdata@Heart and IMI H2O which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement numbers 115902, 806999, 116074 and 945345 respectively. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. See www.imi.europa.eu for more details.

Neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained on this website.

Written by

Jessica Singh